Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with cisplatin/5-fluorouracil-based induction chemotherapy followed by preoperative chemoradiotherapy for resectable locally advanced esophagogastric adenocarcinoma
2009-015402-19Phase 2Completed
- Sponsor
- Erasmus Hospital
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Erasmus Hospital. Primary endpoints: Treatment completion, Excessive toxicity and 1 more. Started Jan 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-015402-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015402-19.